While I was researching my pre-ASH article on our Help With Cancer.org site this morning (that is where I post non-myeloma related cancer news from large oncology conferences like ASH and ASCO), I found this interesting tidbit burried deep in one of Pfizer’s press releases:
A Phase 1 trial evaluating PD 0332991 in combination with bortezomib or dexamethasone in relapsed or refractory multiple myeloma. PD 0332991 is a selective inhibitor of cyclin-dependent kinase (CDK) 4/6.(12)
Pfizer’s emphasis is leukemia and lymphoma. They are also doing some solid tumor work. So I was a bit surprised to discover they will be presenting some Phase 1 multiple myeloma related results. Since Millennium makes bortesomib (Velcade), I will speak with some of my contacts there and see what I can find out.
Feel good and keep smiling! Pat